91271-84-0 Usage
General Description
4-(Morpholinomethyl)benzylamine is an organic chemical compound with the molecular formula C11H16N2O. It is a derivative of benzylamine and contains a morpholine group, making it a tertiary amine. 4-(MORPHOLINOMETHYL)BENZYLAMINE is commonly used as a building block in organic synthesis and pharmaceutical research. Its primary applications include as an intermediate in the production of various drugs and agrochemicals. It is considered to be a versatile and important compound in the field of organic chemistry due to its potential for diversifying chemical structures and creating new molecules with useful properties.
Check Digit Verification of cas no
The CAS Registry Mumber 91271-84-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,1,2,7 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 91271-84:
(7*9)+(6*1)+(5*2)+(4*7)+(3*1)+(2*8)+(1*4)=130
130 % 10 = 0
So 91271-84-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H18N2O/c13-9-11-1-3-12(4-2-11)10-14-5-7-15-8-6-14/h1-4H,5-10,13H2
91271-84-0Relevant articles and documents
Cyano-pyrrolo-heteroaryl derivative, preparation method thereof and application of derivative to medicine
-
, (2019/10/23)
The invention relates to a cyano-pyrrolo-heteroaryl derivative, a preparation method thereof and an application of the derivative to medicine, and particularly relates to a novel cyano-pyrrolo-heteroaryl derivative as shown in a general formula (I), a pre
SUBSTITUTED SULFONAMIDE COMPOUNDS
-
Page/Page column 45-46; 48, (2008/12/06)
Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.
QUATERNARY SALT CCR2 ANTAGONISTS
-
Page/Page column 63-64, (2008/06/13)
Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.
